Literature DB >> 29569361

Commentary: Providing technical assistance for the state targeted response for opioid use disorders: Time is of the essence.

Frances R Levin1,2, Kathryn Cates-Wessel3.   

Abstract

Entities:  

Year:  2018        PMID： 29569361      PMCID： PMC5947319          DOI： 10.1111/ajad.12705

Source DB:  PubMed          Journal:  Am J Addict        ISSN： 1055-0496


× No keyword cloud information.
  10 in total

1.  1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial.

Authors:  Johan Kakko; Kerstin Dybrandt Svanborg; Mary Jeanne Kreek; Markus Heilig
Journal:  Lancet       Date:  2003-02-22       Impact factor: 79.321

2.  Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.

Authors:  Maria Sullivan; Adam Bisaga; Martina Pavlicova; C Jean Choi; Kaitlyn Mishlen; Kenneth M Carpenter; Frances R Levin; Elias Dakwar; John J Mariani; Edward V Nunes
Journal:  Am J Psychiatry       Date:  2017-01-10       Impact factor: 18.112

3.  Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.

Authors:  Paolo Mannelli; Li-Tzy Wu; Kathleen S Peindl; Marvin S Swartz; George E Woody
Journal:  Drug Alcohol Depend       Date:  2014-02-15       Impact factor: 4.492

4.  Nonmedical Prescription Opioid Use and Use Disorders Among Adults Aged 18 Through 64 Years in the United States, 2003-2013.

Authors:  Beth Han; Wilson M Compton; Christopher M Jones; Rong Cai
Journal:  JAMA       Date:  2015-10-13       Impact factor: 56.272

5.  Long-term retention in Office Based Opioid Treatment with buprenorphine.

Authors:  Zoe M Weinstein; Hyunjoong W Kim; Debbie M Cheng; Emily Quinn; David Hui; Colleen T Labelle; Mari-Lynn Drainoni; Sara S Bachman; Jeffrey H Samet
Journal:  J Subst Abuse Treat       Date:  2016-12-30

6.  Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.

Authors:  Lars Tanum; Kristin Klemmetsby Solli; Zill-E-Huma Latif; Jurate Šaltyte Benth; Arild Opheim; Kamni Sharma-Haase; Peter Krajci; Nikolaj Kunøe
Journal:  JAMA Psychiatry       Date:  2017-12-01       Impact factor: 21.596

Review 7.  The cost-effectiveness of methadone maintenance as a health care intervention.

Authors:  P G Barnett
Journal:  Addiction       Date:  1999-04       Impact factor: 6.526

Review 8.  The Opioid Epidemic in the United States.

Authors:  Richard Gentry Wilkerson; Hong K Kim; Thomas Andrew Windsor; Darren P Mareiniss
Journal:  Emerg Med Clin North Am       Date:  2016-02-17       Impact factor: 2.264

9.  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo; Ken Bachrach; Genie L Bailey; Snehal Bhatt; Sarah Farkas; Marc Fishman; Phoebe Gauthier; Candace C Hodgkins; Jacquie King; Robert Lindblad; David Liu; Abigail G Matthews; Jeanine May; K Michelle Peavy; Stephen Ross; Dagmar Salazar; Paul Schkolnik; Dikla Shmueli-Blumberg; Don Stablein; Geetha Subramaniam; John Rotrosen
Journal:  Lancet       Date:  2017-11-14       Impact factor: 79.321

10.  Long-term methadone maintenance reduces protracted symptoms of heroin abstinence and cue-induced craving in Chinese heroin abusers.

Authors:  Jie Shi; Li-Yan Zhao; David H Epstein; Xiao-Li Zhang; Lin Lu
Journal:  Pharmacol Biochem Behav       Date:  2007-04-21       Impact factor: 3.533
  10 in total
  1 in total

1.  Comparing Buprenorphine-Prescribing Physicians Across Nonmetropolitan and Metropolitan Areas in the United States.

Authors:  Lewei Allison Lin; Hannah K Knudsen
Journal:  Ann Fam Med       Date:  2019-05       Impact factor: 5.166
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.